Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligand

An oncolytic virus comprising:

• (i) a nucleic acid sequence encoding a type I interferon, wherein the type I interferon is:
• IFNα comprising at least 80% sequence identity to the human IFNα (SEQ ID NO:
• 1), IFNβ comprising at least 80% sequence identity to the human IFNβ (SEQ ID NO:
• 2), IFNε comprising at least 80% sequence identity to the human IFN& (SEQ ID NO:
• 3), IFNκ comprising at least 80% sequence identity to the human IFNκ (SEQ ID NO:
• 4), or IFNω comprising at least 80% sequence identity to the human IFN (SEQ ID NO:
• 5);
• (ii) a nucleic acid sequence encoding a CD40-L, which comprises at least 80% sequence identity to a chimeric CD40-L having a sequence selected from SEQ ID NOs:
• 7 to 18;
• (iii) a CMV promoter sequence operatively linked to the nucleic acid sequence encoding the CD40L such that expression of the CD40L is directed by the CMV promoter;
• and
• (iv) an SV40 promoter sequence operatively linked to the nucleic acid sequence encoding the type I interferon such that expression of the type I interferon is directed by the SV40 promoter, wherein the oncolytic virus is recombinant adenovirus.